A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

In a randomized trial, 48 weeks of treatment with bulevirtide, which inhibits hepatitis D virus entry into hepatocytes, reduced HDV RNA and alanine aminotransferase levels in patients with chronic hepatitis D.

Uloženo v:

Podrobná bibliografie
Vydáno v:	The New England journal of medicine Ročník 389; číslo 1; s. 22 - 32
Hlavní autoři:	Wedemeyer, Heiner, Aleman, Soo, Brunetto, Maurizia Rossana, Blank, Antje, Andreone, Pietro, Bogomolov, Pavel, Chulanov, Vladimir, Mamonova, Nina, Geyvandova, Natalia, Morozov, Viacheslav, Sagalova, Olga, Stepanova, Tatyana, Berger, Annemarie, Manuilov, Dmitry, Suri, Vithika, An, Qi, Da, Ben, Flaherty, John, Osinusi, Anu, Liu, Yang, Merle, Uta, Schulze zur Wiesch, Julian, Zeuzem, Stefan, Ciesek, Sandra, Cornberg, Markus, Lampertico, Pietro
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Massachusetts Medical Society 06.07.2023
Témata:	Alanine transaminase Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Antiviral drugs Arthralgia Asthenia Biopsy Cirrhosis Coinfection - drug therapy Coinfection - virology Disease Eosinophilia FDA approval Gastroenterology Gastroenterology General Hepatitis B Hepatitis B surface antigen Hepatitis B Surface Antigens Hepatitis B virus - genetics Hepatitis B, Chronic - drug therapy Hepatitis D, Chronic - drug therapy Hepatitis delta virus Hepatitis Delta Virus - genetics Hepatocytes Humans Infections Infectious Disease Infectious Disease General Interferon Liver cirrhosis Liver Disease Liver diseases Pruritus Ribonucleic acid RNA Viral Infections Russia
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!